Loading...
XNYSCOR
Market cap43bUSD
Dec 24, Last price  
227.54USD
1D
-0.04%
1Q
1.84%
Jan 2017
186.68%
Name

Amerisourcebergen Corp

Chart & Performance

D1W1MN
XNYS:COR chart
P/E
29.00
P/S
0.15
EPS
7.85
Div Yield, %
0.95%
Shrs. gr., 5y
-1.12%
Rev. gr., 5y
10.36%
Revenues
293.96b
+12.12%
54,577,321,00061,203,145,00066,074,312,00070,189,733,00071,759,990,00077,953,979,00080,217,558,00078,080,806,00087,959,167,000119,569,127,000135,961,803,000146,849,686,000153,143,826,000167,939,635,000179,589,121,000189,893,926,000213,988,843,000238,587,006,000262,173,411,000293,958,599,000
Net income
1.51b
-13.53%
319,199,000467,714,000469,167,000250,559,000503,397,000636,748,000706,624,0005,048,00018,841,00022,765,00034,706,00058,709,00074,855,00077,922,000855,365,000-3,408,716,0001,539,932,0001,698,820,0001,745,293,0001,509,120,000
CFO
3.48b
-10.91%
1,526,638,000807,265,0001,207,904,000737,069,000783,763,0001,108,624,0001,167,948,0001,305,449,000788,125,0001,463,153,0003,920,379,0003,178,497,0001,489,007,0001,411,388,0002,344,023,0002,207,040,0002,666,586,0002,703,088,0003,911,334,0003,484,685,000
Dividend
Aug 09, 20240.51 USD/sh
Earnings
Jan 29, 2025

Profile

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
IPO date
May 28, 1996
Employees
480
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
293,958,599
12.12%
262,173,411
9.89%
238,587,006
11.50%
Cost of revenue
284,048,570
253,213,918
230,252,441
Unusual Expense (Income)
NOPBT
9,910,029
8,959,493
8,334,565
NOPBT Margin
3.37%
3.42%
3.49%
Operating Taxes
484,702
428,260
516,517
Tax Rate
4.89%
4.78%
6.20%
NOPAT
9,425,327
8,531,233
7,818,048
Net income
1,509,120
-13.53%
1,745,293
2.74%
1,698,820
10.32%
Dividends
(416,168)
(398,752)
(391,687)
Dividend yield
Proceeds from repurchase of equity
(1,453,527)
(1,180,728)
4,598,002
BB yield
Debt
Debt current
576,331
641,344
1,070,473
Long-term debt
3,811,745
5,994,607
5,654,832
Deferred revenue
5,372,471
5,782,032
Other long-term liabilities
6,582,381
960,486
976,583
Net debt
1,255,428
3,980,784
3,276,746
Cash flow
Cash from operating activities
3,484,685
3,911,334
2,703,088
CAPEX
(487,173)
(458,359)
(496,318)
Cash from investing activities
(618,096)
(2,602,465)
(368,437)
Cash from financing activities
(2,330,994)
(2,222,278)
(1,752,780)
FCF
9,199,734
11,875,604
8,035,003
Balance
Cash
3,132,648
2,592,051
3,388,189
Long term investments
63,116
60,370
Excess cash
Stockholders' equity
4,568,825
3,732,151
1,432,435
Invested Capital
11,757,199
13,352,292
12,454,496
ROIC
75.07%
66.12%
57.81%
ROCE
73.95%
59.69%
58.89%
EV
Common stock shares outstanding
200,284
204,591
211,210
Price
Market cap
EV
EBITDA
11,028,871
9,923,397
9,044,400
EV/EBITDA
Interest
156,991
228,931
210,673
Interest/NOPBT
1.58%
2.56%
2.53%